1 tracked superinvestor hold Xenon Pharmaceuticals Inc (XENE), worth $14M combined, led by Stanley Druckenmiller. Smart money is holding XENE as of the latest 13F filings.
Current price
$59.75
+54.6%
1Y
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase…
Market cap
$4.4B
P/E
-12.87
Div yield
0.0%
Revenue YoY
0.0%
Analyst target
$87
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$14M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
0
0 buying · 0 selling
Smart money is holding XENE steady this quarter — buys and sells are balanced.
Xenon Pharmaceuticals Inc (XENE) is held by 1 tracked funds worth $14M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Stanley Druckenmiller at 0.3% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0.3% | $14M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
1 insider filed SEC Form 144 for $641K of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Steven Gannon | Director | 10,000 | $641K | 2026-08-13 |
Which superinvestors own XENE?
1 tracked funds hold Xenon Pharmaceuticals Inc (XENE), the largest being Stanley Druckenmiller (Duquesne Family Office) at 0.3% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling XENE?
In the most recent 13F quarter, 0 tracked funds added or opened XENE and 0 trimmed it.
How much XENE do tracked funds hold?
Combined disclosed long exposure to XENE across tracked superinvestors is $14M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.